Browse News
Filter News
Found 11 articles
-
Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
1/12/2023
Versanis Bio today announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the U.S., Australia, and New Zealand.
-
Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022
11/2/2022
Versanis Bio today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego.
-
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.
-
Versanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles
10/18/2022
Versanis Bio ("Versanis"), a clinical stage company advancing novel therapeutics for people living with obesity and cardiometabolic diseases, today announced two key leadership appointments.
-
Five years after joining Johnson & Johnson as head of research and development, Mathai Mammen is leaving abruptly to seek other opportunities outside the company.
-
The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly's drug. Here's all that you need to know.
-
Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity
7/20/2022
Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments.
-
Versanis Bio's data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.
-
Versanis Presents Data Demonstrating Bimagrumab Treatment Leads to Substantial Fat Mass Loss Coupled with Lean Mass Gain in Diabetic and Non-Diabetic Patients
6/11/2022
Versanis Bio will share analysis of Phase 2 data from prior studies of lead asset bimagrumab at ENDO 2022, being held virtually and in Atlanta June 11-14, 2022.
-
Newly launched Versanis Bio is aiming to turn a Novartis drug that was once developed to help with muscle loss and weakness into an anti-obesity treatment.
-
Adicet Bio Announces Formation of Scientific Advisory Board
7/15/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the formation of a Scientific Advisory Board.